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Abstract
Introduction: Statins have pleiotropic effects that could influence the prevention and outcome of some infectious diseases.
There is no information about their specific effect on Staphylococcus aureus bacteremia (SAB).
Methods: A prospective cohort study including all SAB diagnosed in patients aged$18 years admitted to a 950-bed tertiary
hospital from March 2008 to January 2011 was performed. The main outcome variable was 14-day mortality, and the
secondary outcome variables were 30-day mortality, persistent bacteremia (PB) and presence of severe sepsis or septic
shock at diagnosis of SAB. The effect of statin therapy at the onset of SAB was studied by multivariate logistic regression and
Cox regression analysis, including a propensity score for statin therapy.
Results: We included 160 episodes. Thirty-three patients (21.3%) were receiving statins at the onset of SAB. 14-day mortality
was 21.3%. After adjustment for age, Charlson index, Pitt score, adequate management, and high risk source, statin therapy
had a protective effect on 14-day mortality (adjusted OR= 0.08; 95% CI: 0.01–0.66; p = 0.02), and PB (OR= 0.89; 95% CI: 0.27–
1.00; p = 0.05) although the effect was not significant on 30-day mortality (OR = 0.35; 95% CI: 0.10–1.23; p = 0.10) or
presentation with severe sepsis or septic shock (adjusted OR= 0.89; CI 95%: 0.27–2.94; p = 0.8). An effect on 30-day mortality
could neither be demonstrated on Cox analysis (adjusted HR= 0.5; 95% CI: 0.19–1.29; p = 0.15).
Conclusions: Statin treatment in patients with SAB was associated with lower early mortality and PB. Randomized studies
are necessary to identify the role of statins in the treatment of patients with SAB.
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Introduction
Statins act as selective and competitive inhibitors of HMG-CoA
reductase. This enzyme converts 3-hydroxy-3-methyl glutaril-
coenzime A into mevalonate, which is a precursor of sterols. The
hypolipidemic action of statins is due to the inhibition of synthesis
of cholesterol in the liver and the increase of the number of liver
receptors for LDL cholesterol. In addition to this activity, other so-
called pleiotropic effects have been described for statins, including
anti-inflammatory, inmunomodulatory, antioxidant and anticoag-
ulant activities [1,2]. Multiple studies have evaluated the effect of
statins in the prevention and prognosis of diverse infectious
diseases. Most of these studies ascribed a beneficial effect to
exposition to statins [3–6]. However, other studies did not found
any benefit or even showed harmful effects [7–9]. In patients with
bloodstream infections (BSI), the use of statins was associated with
lower mortality in a recent meta-analysis [10].
Staphylococcus aureus is one of the most important etiological
agents of both nosocomial and community-onset BSIs [11,12]; S.
aureus bacteremia (SAB) is associated with important morbidity
and mortality [13]. To our knowledge, there are no studies
specifically investigating the effect of statins in the outcome of
patients with SAB, in spite of the fact that in vitro and animal
model data suggest that they may play a role [14,15]. It has been
hypothesized that this effect could be linked to the inhibition of
host cell invasion. This inhibition would facilitate the extracellular
activity of antibiotics, avoid intracellular persistence, and so reduce
the hematogenous spread of S. aureus [14].
The aim of our study is, therefore, to assess the effect of the
treatment with statins on the evolution and prognosis of SAB.
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Methods
Setting, patients, and study design
A prospective cohort study including all episodes of SAB
diagnosed in patients aged $18 years admitted to Hospital
Universitario Virgen Macarena (a 950-bed tertiary hospital
located in Seville, Spain) from March 2008 to January 2011 was
carried out. A specific ‘‘bacteremia program’’, carried out by
clinical microbiologists and infectious diseases physicians is active
in our hospital since 2003; the program includes early personalized
reporting of blood culture results and unsolicited management
advice for all patients with BSI [16]. Patients with SAB were
detected through daily review of microbiology reports. SAB was
defined as the isolation of S. aureus from at least one blood culture
in patients with symptoms or signs of infection. Only one episode
(the first) per patient was included in the analysis. Patients were
followed for 90 days after the diagnosis of SAB. An experienced
team of clinical microbiologists and infectious diseases doctors
followed all included patients daily during their admission; the
evolution of surviving patients discharged before day 30 was
assessed by outpatient clinic visits and/or phone calls. The data
were collected by one investigator (LELC) using a structured
questionnaire and reviewed by a senior investigator (JRB). This
analysis was reported following the STROBE recommendations
[17]. The study was approved by the Ethic Committee of Hospital
Universitario Virgen Macarena which waived the need to
obtained written informed consent from patients because of the
observational nature of the study.
Variables and definitions
The main outcome variable was all-cause 14-day mortality, and
the secondary outcome variables were all-cause 30-day mortality,
persistent bacteremia (PB; see definition below) and presence of
severe sepsis or septic shock at diagnosis of SAB. The outcome
variables and their definitions were decided and defined previ-
ously. The reasons for choosing 14-day mortality as main outcome
variable are explained in the Discussion.
The main exposure variable was therapy with statins. For the
purpose of the study, patients were considered to be receiving
statins if they had been treated with any drug belonging to this
family (including pravastatin, atorvastatin, simvastatin, fluvastatin,
lovastatin and pitavastatin) for at least 30 days and were still taking
them when SAB was diagnosed. Exposure to statins was assessed
by reviewing the charts and by directly interviewing the patients or
their relatives. Other exposure variables considered included
demographics, types and severity of underlying conditions, type of
acquisition of SAB, source of infection, severity of systemic
inflammatory response syndrome (SIRS) at presentation, antimi-
crobial therapy, and support therapy.
We used the Charlson comorbidity index to measure the
severity of chronic underlying conditions [18]; this index has been
validated as a mortality predictor in SAB [19]. The acute severity
of the illness was retrospectively assessed on the day before the
diagnosis of SAB using the Pitt bacteremia score, which has also
been validated [20]. SAB were considered as hospital-acquired if
occurring after 48 hours of hospital stay, and as community-onset
in all other cases. The source of infection was established by the
agreement between 2 investigators according to clinical and
microbiological criteria. Sources of SAB associated with high
mortality in previous studies were classified as high-risk sources;
these included endocarditis, unknown source, endovascular
infections other than catheter-related, central nervous system
infections, and respiratory tract infections [21,22]. The severity of
SIRS was classified as sepsis, severe sepsis or septic shock
according to standard definitions [23]. Clinical management was
considered adequate when it fulfilled all the following criteria:
appropriate antimicrobial therapy was administered (at least one
active drug was administered during the first 24 hours, and active
drugs were administered as definitive therapy); fluid resuscitation
was administered in patients with severe sepsis or septic shock
according to recommendations [24]; respiratory support was
provided according to recommendations [24]; duration of
treatment was according to complexity of infection [16,25,26];
and the source of infection was removed or drained whenever
feasible [16,27,28]; otherwise, it was considered non-adequate.
Persistent SAB was defined as the isolation of S. aureus in blood
cultures obtained from peripheral veins for $3 days despite
appropriate antimicrobial therapy according to susceptibility
testing.
Microbiological Studies
Two or three sets of two blood samples, separated by 20–
30 minutes and containing 15 mL of blood each, were drawn in
patients who presented fever $38uC or when bacteremia was
suspected because of clinical signs or symptoms. Blood samples
were processed by API Staph system (BioMerieux, NC, USA). The
identification of the isolates was assessed by API Staph (BioMer-
ieux, NC, USA), and antimicrobial susceptibility was studied by
WIDER (Soria Melguizo, Madrid, Spain) and microdilution
according to the recommendations by the Clinical and Laboratory
Standards Institute (CLSI) [29].
Statistical analysis
Crude comparisons were performed by using the Chi squared
or Fisher tests as appropriate for percentages, and the Mann-
Whitney U test for continuous variables. Multivariate analyses
were performed by using logistic regression. Variables with a p
value,0.2 in the univariate analysis were included. Selection of
variables was performed using a stepwise backward process,
variables with a p value,0.2 were kept in the models. Effect
modifications between the exposure of interest and other variables
were investigated. A propensity score for receiving statins was
added to the models. The propensity score (the probability of
receiving statins) was calculated using a non-parsimonious
multivariate logistic regression model, in which the outcome
variable was use of statins; all variables considered as potentially
influencing the prescription of statins, including gender, service of
admission, type of acquisition, all underlying diseases, recent
surgery, and indwelling implants, were included. The validity of
the models was assessed by estimating goodness-of-fit to the data
with the Hosmer-Lemeshow test, and its discrimination ability
with the area under the receiver operating characteristic (ROC)
curve. A survival analysis, using time until death (limited to 30
days) or censorship as outcome variable was also performed.
Bivariate comparison of Kaplan Meier curves was performed by
log rank test, and multivariate analysis was carried out by Cox
regression modelling. The software used for the analysis was SPSS
v17.0.
Results
We included 160 episodes of SAB during the thirty five months
of the study period. Thirty-three patients (21.3%) were receiving
statins at the onset of SAB (all of them had been receiving these
drugs for at least one month): 17 (5.15% of those receiving statins)
received atorvastatin, 14 (42.4%) simvastatin, and 2 (6%)
pravastatin. The epidemiological and clinical features of patients
receiving and not receiving statins are shown in Table 1. Diabetes
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mellitus and catheter-related bacteremia were more frequent
among patients who were receiving statins. The treatment and
outcomes are also shown in Table 1. Mortality at day 14 and 30
were 21.3% and 28.7%, respectively; crude comparison showed
lower 14-day mortality in the statins group; the differences for PB
and 30-day mortality were in the limit of significance.
The univariate analysis of the association of exposure to
categorical variables and 14-day mortality is shown in Table 2.
Apart from statin use, other variables showing a crude association
with 14-day mortality were the source of bacteremia, non-adequate
clinical management, and presentation with severe sepsis and septic
shock. As regards the continuous variables [measured as median
value (interquartile range)], age and Pitt score were significantly
higher among patients who died [age in years: 75 (63–83) vs. 66 (58–
75), p = 0.01; Pitt score: 3 (2–4) vs. 1 (0–2), p,0.001, respectively],
but Charlson index was not [2 (2–4) vs. 2 (1–3), p = 0.09].
We calculated a propensity score for receiving statins. The
model showed a p value of 0.42 for the Hosmer-Lemeshow
goodness-of-fit test, and an area under the ROC curve of 0.877,
showing good predictive ability for receiving statins. In order to
control for confounding in the association between statins and 14-
day mortality, we performed several multivariate analysis by
logistic regression. The variables introduced were age, Charlson
index, Pitt score, high risk source, adequate clinical management,
and statin use, plus the propensity score. Neither presentation with
severe sepsis/septic shock nor PB was introduced in the model
because these variables are in the pathogenic pathway between
development of SAB and death, and exposure to statins preceded
them. Because the source of bacteremia was an important
predictor of outcome (Table 2) and the distributions of SAB
sources were different among patient exposed and not exposed to
statins, we performed different analysis to control for this
confounder. To do so, we performed 4 multivariate models for
which the variable source was defined in different ways (Table 3).
Statin therapy was independently associated with statin therapy in
all of them. All models showed a high prediction ability; as an
Table 1. Features of patients with Staphylococcus aureus bacteremia.
Variable Subcategory All patients (n = 160) Statin use (n = 33) No statin use (n = 127) p-value
Median age (interquartile range),
years
68 (59–77) 67 (63–75) 68 (58–77) 0.4
Male sex 100 (63) 23 (69.7) 77 (60.6) 0.3
Comorbidities
Chronic heart failure 28 (17.5) 3 (9.1) 16 (12.6) 0.5
Chronic pulmonary disease 34 (21.3) 4 (12.1) 24 (18.9) 0.3
Malignancy 63 (39.4) 6 (18.2) 28 (22) 0.6
Diabetes mellitus 19 (11.9) 20 (60.6) 43 (33.9) 0.005
Chronic heart failure 19 (11.9) 3 (9.1) 16 (12.6) 0.5
Hemodialysis 12 (7.5) 4 (12.1) 8 (6.3) 0.2
Intravenous drug abuse 5 (3.1) 0 (0) 5 (3.9) 0.2
Organ transplantation 1 (0.3) 0 (0) 1 (0.8) 0.6
Median Charlson index 2 2 3 0.1
Median Pitt score 2 2 2 0.8
Hospital-acquired infection 93 (58.1) 22 (66.7) 71 (55.9) 0.2
Source of BSI
Vascular catheter 69 (43.1) 23 (69.7) 46 (36.2) 0.001
Unknown source 30 (18.8) 4 (12.1) 26 (20.5) 0.2
Respiratory tract 11 (6.9) 0 (0) 11 (8.7) 0.08
Skin and/or soft tissue 24 (15) 6 (18.2) 18 (14.2) 0.5
Endocarditis 4 (2.5) 0 (0) 4 (3.1) 0.9
Others 22 (13.7) 0 (0) 22 (100) 0.1
High risk source# 48 (42.8) 4 (12.1) 44 (34.6) 0.01
Methicillin-resistant S. aureus 26 (16.3) 4 (12.1) 22 (17.3) 0.4
ICU admission 42 (26.3) 10 (30.3) 32 (25.2) 0.5
Adequate management 145 (90.6) 30 (90.9) 115 (90.6) 0.9
Outcome variables
14-day mortality 34 (21.3) 2 (6) 32 (25.2) 0.01
30-day mortality 46 (28.7) 5 (15.2) 42 (32.3) 0.05
Persistent bacteremia* 34/150 (22.7) 3/31 (9.7) 31/119 (26.1) 0.05
Severe sepsis or septic shock 38 (23.7) 6 (18.2) 33 (25.2) 0.5
*Patients who died within 96 hours are excluded.
#High risk source: endocarditis, unknown source, endovascular infections other than catheter-related, central nervous system infections, and respiratory tract infections.
Data are expressed as number of cases (percentage) except where specified.
doi:10.1371/journal.pone.0082958.t001
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example, model 1, in which source was classified as high or low-
risk, showed a p value of 0.63 for the Hosmer-Lemeshow
goodness-of-fit test, and an area under the ROC curve of 0.90.
Additionally, we performed another model (not shown) in which
source was defined as a polichotomous variable (including
catheter, which was taken as reference, respiratory tract, unknown,
and others); in this model, statin therapy remained associated with
lower 14-day mortality (adjusted OR = 0.08; CI 95%: 0.01–0.83;
p = 0.03). Finally, because the models might be overfitted due to
the high number of variables introduced in relation to the number
of patients with the event, we also performed several models in
which the variables were added to statins in a forward approach to
a limit of 3. Statin therapy showed a protective effect for 14-day
mortality in all of them (data not shown). We also performed a
survival analysis until day 30. The Kaplan Meier curves are shown
in figure 1; the log rank value for mortality among patients who
received and not received statins was 0.06. The Cox regression
model including the propensity score, did not show association of
statin use with 30-day mortality (adjusted HR = 0.5; 95% CI:
0.19–1.29; p = 0.15).
We also performed multivariate analyses for secondary outcome
variables. An independent relationship between statin use and
these variables could not be demonstrated using a similar strategy,
neither for 30-day mortality (adjusted OR = 0.35; 95% CI: 0.10–
1.22; p = 0.10) nor for presentation with severe sepsis or septic
shock (adjusted OR = 0.89; CI 95%: 0.27–2.94; p = 0.8). However,
statins use showed a protective effect for PB (adjusted OR = 0.89;
95% CI: 0.27–1.00; p = 0.05).
In the subgroup analyses, statin therapy showed the following
association to 14-day mortality: among nosocomial SAB,
OR = 0.08; CI 95%: 0.005–1.27; among community-onset SAB,
OR = 0.81; CI 95%: 0.21–3.27; among patients aged #60 years,
OR = 0.43; CI 95%: 0.02–6.95; among those older than 60 years,
OR = 0.25; CI 95%: 0.006–0.98; among patients with a Charlson
index #1, OR = 0.38; CI 95%: 0.02–6.23; finally, among those
with a Charlson index $2, OR = 0.25; CI 95%: 0.06–0.98.
Table 2. Univariate analysis of 14-day mortality among patients with S. aureus bacteremia according to exposure to different
categorical variables.
Variable Subcategory No. dead/No. exposed(percentage) RR (95% CI) P value
Gender Male 19/100 (19) Ref.
Female 15/60 (25) 0.76 (0.41–1.38) 0.3
Source
Catheter 6/69 (8.7) Ref. Ref.
Respiratory 8/11 (72.7) 8.36 (3.58–19.48) ,0.001
Unknown 9/30 (30) 3.45 (1.34–8.83) 0.009
Skin and/or soft tissue 6/24 (25) 2.87 (1.02–8.06) 0.04
Endocarditis 2/4 (50) 5.75 (1.65–19.92) 0.01
Others 2/12 (16.7) 1.91 (0.43–8.44) 0.86
Type of acquisition
Community-onset 14/67 (20.9) Ref.
Nosocomial 20/93 (21.5) 0.97 (0.53–1.78) 0.9
Persistent bacteremia"
Yes 7/34 (20.6) 1.41 (0.53–3.72) 0.4
No 18/116 (15.5) Ref.
Severe sepsis or septic shock
Yes 21/35 (60) 12.92 (5.32–31.38) ,0.001
No 13/125 (10.4) Ref.
Susceptibility
MRSA 5/26 (19.1) Ref.
MSSA 29/134 (21.6) 1.12 (0.48–2.63) 0.7
Empirical treatment
Appropriate 24/122 (19.7) Ref.
Non-appropriate 10/38 (26.3) 1.33 (0.70–2.54) 0.3
Clinical management
Adequate 25/145 (17.2) 0.24 (0.06–0.94) ,0.001
Non-adequate 9/15 (60) Ref.
Statins use
Yes 2/33 (6.1) 0.24 (0.06–0.94) 0.01
No 32/127 (25.2) Ref.
"Considered only among surviving patients at 96 hours.
MRSA: Methicillin-resistant S. aureus. MSSA: Methicillin-susceptible S. aureus.
doi:10.1371/journal.pone.0082958.t002
Statins & S. aureus Bacteremia
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e82958
Figure 1. Kaplan-Meier survival curves for patients receiving and not receiving statins.
doi:10.1371/journal.pone.0082958.g001
Table 3. Different multivariate models for 14-day mortality.
Model1 Model 2 Model 3 Model 4
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Statins use 0.08 (0.01–0.67) 0.02 0.09 (0.01–0.70) 0.02 0.08 (0.01–0.74) 0.03 0.07 (0.01–0.49) 0.008
Age (per unit) 1.05 (1.01–1.09) 0.007 1.05 (1.01–1.08) 0.02 1.06 (1.02–1.10) 0.006 1.05 (1.01–1.09) 0.01
Charlson index
(per unit)
1.26 (0.98–1.62) 0.06 1.20 (0.93–1.55) 0.16 1.20 (0.93–1.53) 0.16 1.21 (0.96–1.55) 0.11
Pitt score (per unit) 1.79 (1.31–2.46) ,0.001 1.82 (1.34–2.46) ,0.001 1.81 (1.33–2.49) ,0.001 1.77 (1.34–2.41) ,0.001
Source according to
below definition*
5.72 (2.07–15.79) 0.001 12.86 (2.54–65.21) 0.002 0.13 (0.04–0.46) 0.002 1.91 (0.63–5.79) 0.26
Adequate
management
0.09 (0.02–0.42) 0.002 0.09 (0.02–0.38) 0.001 0.06 (0.01–0.29) 0.001 0.12 (0.03–0.46) 0.002
*Source was defined as a dichotomous variable as follows. Model 1: high risk source (endocarditis, unknown source, endovascular infections other than catheter-related,
central nervous system infections, and respiratory tract infections) vs. low risk source. Model 2: respiratory source vs. other sources. Model 3: catheter-related source vs.
other sources. Model 4: Unknown source vs. known source.
The propensity score for including statins was included in all of them. The definition for the variable source was different in each model (see footnote).
doi:10.1371/journal.pone.0082958.t003
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Discussion
We found an association between statin therapy and reduced
risk of early death among patients with SAB. Such association
could not be demonstrated for 30-day mortality.
We chose 14-day mortality as our main outcome variable
because our hypothesis was that statin therapy may have an
impact in early, acute infection-related mortality, and we
considered this time frame would adequately represent the
biological plausible window of effect, as has been recommended
[30]. Since mortality in patients with SAB may be due either to a
direct effect of the infection (because of septic shock, respiratory
distress, disseminated intravascular coagulation) or to later
complications related to endocarditis or metastatic lesions, and
also to decompensation of underlying conditions or other non-
infection-related caused, early mortality is more probably related
to the direct impact of the infection rather than to late metastatic
complications or unrelated issues.
Patients receiving statins were similar to those not exposed to
these drugs in demographic features and underlying conditions
except diabetes mellitus. This was expected because diabetes
mellitus is frequently associated with dyslipidemia, which would
increase the probability of receiving statins due to a higher
cardiovascular risk. Patients with statins had a higher frequency of
catheter-related SAB and a trend towards lower frequency of
respiratory tract infection-related SAB, which would clearly
reduce their baseline risk of mortality, since catheter-related BSI
is usually associated with lower mortality while the opposite is seen
with respiratory tract infections [13]. These and other potential
confounders were controlled by performing multivariate analyses
in which a propensity score for receiving statins was also used.
The association of statin treatment with lower mortality in
different types of infection has been previously described, but there
are scarce data about S. aureus. A recent meta-analysis assessed the
effect of statins on all-cause mortality among patients with severe
infections [10]; the pooled analysis showed an overall survival
benefit in patients receiving statins. Bacteremia-related mortality
was reported in 4 of these studies; a meta-analysis of this subgroup
of studies also showed a lower rate of bacteremia-related mortality
in patients receiving statins (OR = 0.33; 95% CI: 0.09–0.75);
specific data for SAB were not provided. In a cohort of 388
patients with BSI of diverse etiologies, statins use was associated
with a 17% decrease in the attributable mortality [31]; however, in
the sub-analysis performed in SAB patients the decrease in
mortality was not statistically significant (no multivariate analysis
in patients with SAB was performed). To our knowledge, there are
no other studies specifically addressing the impact of statins on
mortality among patients with SAB, although there are some
features of SAB that worth a specific investigation: SAB is more
frequently persistent and complicated than bacteremia due to
other microorganisms [32–34], and clinical management has been
consistently shown to influence the outcome [23–26,35].
The pathophysiological basis for the potential association
between statin treatment and lower mortality in some infectious
diseases is still unknown. In our study, patients under statin
therapy developed severe sepsis and septic shock with less
frequency, but the difference was not statistically significant, and
multivariate analysis could not show a protective effect of statins
for developing severe systemic inflammatory response syndrome
(SIRS). This is in contrast to previous observations in patients with
infections due to other microorganisms [36,37]. Beyond the
potential effect on the development of severe SIRS, we found that
patients receiving statins had a lower frequency of PB. PB has been
associated with increased mortality in previous studies of SAB
[30,38,39]. PB has been shown to be related to some hosts’
features as well as to clinical management [39,40]. However, the
molecular mechanisms involved in PB are poorly known. It is
known that secretion of platelet microbicidal proteins (PMPs) and
intracellular killing by neutrophil-associated oxidative and non-
oxidative mechanisms are involved in the initial phases of vascular
invasion leading to bacteremia [27,41,42]. On the other hand,
Xiong et al. [34] showed that MRSA causing PB tend to be more
resistant to key innate cationic host defense molecules from both
neutrophils (e.g., hNP-1) and platelets (e.g., tPMP-1), have more
enhanced membrane fluidity, and substantially greater adhesion to
fibronectin, fibrinogen, and endothelial cells. Also, isolates causing
PB adhere better to host cells (i.e., endothelium) and matrix
ligands relevant to endovascular pathogenesis (i.e., fibrinogen and
fibronectin) [34]. Simvastatin has been shown to inhibit cell
invasion by S. aureus in vitro [14] and to interfere with exotoxine-
induced leukocyte-endothelial cell interactions [15]. Whether the
lower rate of PB in patients treated with statins, if confirmed,
might be related to any of these effects or others [43], would merit
being investigated.
Our study must be interpreted considering its limitations. Since
it is not a randomized study, confounding due to unmeasured
variables may not have been controlled. However, we made a
great effort to control the potential confounding factors, including
a propensity analysis and performing several multivariate models.
The healthy user effect (patients receiving statins may be subject to
better medical follow-up and a healthier lifestyle) needs to be taken
into account [44]. Although our propensity score analysis could
not discard this effect, we do not think it is a relevant issue since
the effect was also significant in patients with nosocomial
infections. Our study does not allow determining whether the
effect of statins is immediate or it requires a minimum treatment
time to be established, as it is the case of the hypolipidemic effect.
Finally, since most of the patients were treated with atorvastatin or
simvastatin (91%), we cannot assess differences in the impact of
specific statins. The fact that we could not find an effect on 30-day
mortality may be due to a lack of longer effect of statins, or to the
limited statistical power of the study. Finally, we did not study the
molecular features of the S. aureus isolates.
Conclusion
In conclusion, in this prospective observational study, treatment
with statins showed a protective effect for 14-day mortality and PB
among patients with BSA. Further studies are needed to determine
the role of statins in the treatment of patients with BSA.
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